DE602004029993D1 - Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit - Google Patents

Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit

Info

Publication number
DE602004029993D1
DE602004029993D1 DE602004029993T DE602004029993T DE602004029993D1 DE 602004029993 D1 DE602004029993 D1 DE 602004029993D1 DE 602004029993 T DE602004029993 T DE 602004029993T DE 602004029993 T DE602004029993 T DE 602004029993T DE 602004029993 D1 DE602004029993 D1 DE 602004029993D1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
independence
drug
treatment
drug dependence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004029993T
Other languages
German (de)
English (en)
Inventor
Shigetada Nakanishi
Takatoshi Hikida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of DE602004029993D1 publication Critical patent/DE602004029993D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602004029993T 2003-02-27 2004-02-26 Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit Expired - Lifetime DE602004029993D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44986803P 2003-02-27 2003-02-27
PCT/JP2004/002301 WO2004075916A1 (en) 2003-02-27 2004-02-26 Pharmaceutical composition for treatment of drug dependence

Publications (1)

Publication Number Publication Date
DE602004029993D1 true DE602004029993D1 (de) 2010-12-23

Family

ID=32927586

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004029993T Expired - Lifetime DE602004029993D1 (de) 2003-02-27 2004-02-26 Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit

Country Status (8)

Country Link
US (1) US20060058336A1 (cg-RX-API-DMAC7.html)
EP (1) EP1603595B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006519225A (cg-RX-API-DMAC7.html)
AT (1) ATE487492T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004216360B2 (cg-RX-API-DMAC7.html)
CA (1) CA2516618A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004029993D1 (cg-RX-API-DMAC7.html)
WO (1) WO2004075916A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
AU2002340232A1 (en) * 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
WO2006013546A2 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Process for the preparation of pure galantamine
RU2491067C2 (ru) * 2007-08-06 2013-08-27 Байотай Терапис, Инк Способы лечения зависимости
CN102573848A (zh) * 2009-04-24 2012-07-11 济州大学校产学协力团 含有去甲加兰他敏化合物作为活性成分的用于预防和治疗脱发症的组合物
KR101037235B1 (ko) 2009-04-24 2011-05-25 충남대학교산학협력단 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 방지 및 발모 개선용 조성물
KR101037237B1 (ko) 2009-04-24 2011-05-25 충남대학교산학협력단 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 질환의 예방 및 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE69229781T2 (de) * 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
ES2223049T3 (es) * 1994-04-29 2005-02-16 Pfizer Inc. Amidas aciclicas y ciclicas novedosas como estimuladores de la liberacion de neurotransmisores.
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
PL181582B1 (pl) * 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
US5824684A (en) * 1997-02-21 1998-10-20 Synapse Pharmaceuticals International, Inc. Method for treating drug and alcohol addiction
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
DK1024807T3 (da) * 1997-08-08 2003-08-04 Medosan Ricerca Srl Anvendelse af forbindelsen 2-methoxyphenyl-1-methyl-5p-methylbenzoyl-pyrrol-2-acetamidoacetat for fremstilling af et anti-inflammatorisk medikament med forhindring af gastrisk hypersecernering og forstyrrelse af nyrefunktionen
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
JP3992806B2 (ja) * 1997-12-12 2007-10-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 ドネペジル中間体の製造法
IL125809A (en) * 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
DE60124730T2 (de) * 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
WO2002049459A1 (en) * 2000-12-20 2002-06-27 Michigan Biotechnology Institute Soy milk juice beverage
DE10119862A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
WO2003024450A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
AU2002340232A1 (en) * 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
JP2004189706A (ja) * 2002-12-13 2004-07-08 Eisai Co Ltd 高度アルツハイマー型痴呆治療剤
US20050018839A1 (en) * 2003-07-23 2005-01-27 Weiser William Bruce Electronic device cradle organizer

Also Published As

Publication number Publication date
US20060058336A1 (en) 2006-03-16
WO2004075916A1 (en) 2004-09-10
EP1603595A4 (en) 2008-04-16
EP1603595A1 (en) 2005-12-14
JP2006519225A (ja) 2006-08-24
AU2004216360B2 (en) 2009-09-17
AU2004216360A1 (en) 2004-09-10
CA2516618A1 (en) 2004-09-10
EP1603595B1 (en) 2010-11-10
AU2004216360A2 (en) 2004-09-10
ATE487492T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
MX2009011512A (es) Nuevos compuestos peptidos ciclicos.
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
DE112004000961D2 (de) Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
GB2446341A (en) Method and system for transdermal drug delivery
ATE413171T1 (de) Pharmazeutische zusammensetzungen mit ascorbinsäure zur behandlung von pilz- superinfektionen und pilz-rezidiven
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
ATE487492T1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
EP4285910A4 (en) Pharmaceutical composition for treatment of neuroinflammation, comprising eleutheroside b as active ingredient
ATE454896T1 (de) Heilkräuterzusammensetzung zur behandlung von aids
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
DK1716128T3 (da) Substituerede 4,5,6,7-tetrahydrobenzothiazol-2-ylaminforbindelser